iCad (Nasdaq:ICAD) announced today that its board of directors approved the appointment of Daniel Shea as interim CFO. Shea takes over as interim CFO, effective immediately. The cancer detection and therapy tech company also launched a search for a full-time CFO. Steve Sarno previously held the interim CFO role. The company said in a news […]
iCad Inc.
iCad, Solis Mammography partner on AI for cardiovascular disease
iCad (Nasdaq:ICAD) announced today that it entered into a collaboration with Solis Mammography to define cardiovascular risk. The development and commercial collaboration revolves around producing an artificial intelligence (AI) solution. This solution potentially quantifies the presence of breast arterial calcifications in a mammogram to assess the risk of cardiovascular disease (CVD). It uses data obtained […]
iCad names Stacey Stevens as CEO
iCad (NSDQ:ICAD) today announced that it has appointed Stacey Stevens as president and CEO, effective March 1, 2022. Stevens has served as the Nashua, N.H.-based company’s president since 2019. She succeeds chairperson and CEO Michael Klein, who will continue to serve as chairperson of iCad’s board of directors. “We are currently at an important inflection point, […]
Latest iCad 3D mammography AI gains CE mark
iCad (NSDQ:ICAD) today announced that the third version of its ProFound AI for digital breast tomosynthesis (DBT) has won CE mark approval. Compared with previous software versions, the latest generation of ProFound AI offers up to a 10% improvement in specificity performance while maintaining a high sensitivity level, and approximately 40% faster processing on the new […]
iCad raises $12.5m
iCad (NSDQ:ICAD) announced that it entered into agreements for the purchase and sale of its common stock for gross proceeds of approximately $12.5 million. The agreements included the sale of more than 1.5 million shares of Nashua, N.H.-based iCad’s common stock at $8 per share. Craig-Hallum Capital Group is acting as financial advisor in connection with […]
iCad’s AI-assisted mammography tech wins CE Mark
iCad (NSDQ:ICAD) has won the CE Mark for its advanced artificial intelligence technology and workflow solution, ProFound AI for 2D mammography. The Nashua, N.H.-based cancer detection and radiation therapy devices maker developed the technology to boost breast cancer detection by identifying soft-tissue densities and calcifications. ProFound AI for 2D mammography is the latest addition to […]
iCad closes $10m offering
iCad (NSDQ:ICAD) yesterday closed a stock offering, including an underwriters option, that grossed more than $10 million. The Nashua, N.H.-based cancer detection and radiation therapy devices maker floated nearly 1.9 million shares at $5.50 apiece, including the 245,500-share over-allotment, for gross proceeds of roughly $10.3 million. The net proceeds of $9.5 million are earmarked for working […]
iCad prices $9m offering
iCad (NSDQ:ICAD) today priced a stock offering that’s slated to gross just more than $9.0 million. The Nashua, N.H.-based cancer detection and radiation therapy devices maker said it plans to float more than 1.6 million shares at $5.50 apiece, for expected net proceeds of about $8.3 million. The offering includes a 30-day underwriters option on […]
Wright Medical creates digital arm, promotes Asper to chief digital officer | Personnel Moves – May 7, 2019
Wright Medical (NSDQ:WMGI) said today that it is creating a new digital division and that it is promoting strategy, tech & corporate dev senior VP Jason Asper to chief digital officer. The new CDO title comes alongside Asper’s existing responsibilities, Amsterdam-based Wright Medical said. The new digital division will focus on the company’s digital surgery strategy […]
ReShape taps Allergan vet Bandy for CEO | Personnel Moves, April 3 2019
ReShape Lifesciences (NSDQ:RSLS) said last week that it named Allergan (NYSE: AGN) veteran Barton Bandy to replace Dan Gladney in the corner office, effective April 1. Gladney, who announced his retirement in January, is staying on as chairman. Bandy spent a decade at Inamed until its $3.2 billion purchase by Allergan in 2005. “I am […]
ReShape Lifesciences CEO Gladney to resign | Personnel Moves – January 29, 2019
ReShape Lifesciences (NSDQ:RSLS) said yesterday that its prez & CEO Dan Gladney will resign from his positions with the company, effective March 31. Gladney will remain with the company as board chair, San Clemente, Calif.-based ReShape Lifesciences said. The company’s board of directors said they will immediately begin to look for a replacement, according to an […]
